Phase 3 N=1,124 Acute Renal Failure Trial Network (ATN) Study
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
N/A N=35 Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure
Acute Renal Failure
Primary: 60 Day Mortality — 11 Participants
N/A N=64,882 Epidemiology of Acute Kidney Injury in England - 1998 to 2013
Acute Kidney Injury
Primary: Secular Trends in the Mortality After Acute Kidney Injury From 1998 to 2013 — 1296; 3763; 19793 participants
N/A N=3,019 Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)
Acute Kidney Injury
Primary: All-cause Mortality. — 639; 643 Participants
N/A N=4,003 Personalized Recommendations for Acute Kidney Injury (AKI) Care
Acute Kidney Injury
Primary: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death — 369; 395…
N/A N=77 Protocol to Assess the Severity of Acute Kidney Injury
Acute Kidney Failure
Primary: Urine Volume — 89; 329; 96; 392 ml
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
N/A N=96 The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury
Acute Kidney Failure
Primary: Progression to Stage 3 AKI — 23 Participants
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
N/A N=73 Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
N/A N=5,060 Drug-Targeted Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
N/A N=2,393 An Electronic Alert System for In-Hospital Acute Kidney Injury
Acute Kidney Injury
Primary: Dialysis Within 7 Days — 87; 70 participants
Phase 2 N=80 The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide.
Cardiorenal Syndrome
Primary: Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values — 8; 5 Participants
N/A N=1,001 Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
Acute Kidney Injury
Primary: The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting…
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
Phase 2 N=123 Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
Kidney Failure, Acute · Renal Replacement Therapy
Primary: Number of Participants Who Developed Acute Kidney Injury Within 72 Hours — 17; 14 Participants
Phase 4 N=66 Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest
Dissection of Thoracic Aorta
Primary: Incidence of Acute Kidney Injury Based on RIFLE Criteria
Phase 2 N=26 Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Phase 2 N=92 Prevention of Acute Kidney Injury in Cardiac Surgery Patients
Kidney Injury
Primary: Number of Participants With Acute Kidney Injury — 20; 14 participants
Phase 3 N=289 Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Phase 3 N=200 High Dose CVVHDF Compared to Standard Dose CVVHDF
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
N/A N=6,030 Optimizing Electronic Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Composite of Progression of AKI, Inpatient Dialysis, or Inpatient Death — 622; 653 Participants — p=0.67
N/A N=30 Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury
Acute Kidney Injury
Primary: Maximum and Minimum Diameters of the Inferior Vena Cava in Patients With Acute Kidney Injury — 1.8; 1.2 cm
N/A N=50 A Study of Acute Kidney Injury in Care Transitions
Acute Kidney Injury
Primary: Number of Subjects to Complete the ACT Program — 22 Participants
Phase 3 N=50 Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Phase 2 N=150 Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
Critically Ill · Acute Kidney Injury
Primary: Death Within 7 Days — 4; 9; 6 Participants — p=0.52